| Title： | Chinese expert consensus on management of diabetes and prediabetes in female breast cancer patients |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians specializing in breast diseases in China. |
| Evidence classification method： | The evidence grading system was developed by incorporating elements of the GRADE system along with insights gleaned from clinical studies conducted in China and expert clinical experience. |
| Development unit： | Society of Clinical Cancer Research Administration of China Anti-Cancer Association / Breast Cancer Rehabilitation Committee of China Anti-Cancer Association |
| Registration time: | 2024-04-30 |
| Registration number： | PREPARE-2024CN603 |
| Purpose of the guideline: | Diabetes and prediabetes in breast cancer patients are widespread and seriously affects the quality of life and prognosis of breast cancer patients. As the overall survival of early breast cancer women continues to increase, blood glucose abnormality is getting attention gradually. However, there is still a lack of targeted guidelines or consensus for the management of diabetes and prediabetes in breast cancer patients. Based on the guideline and the clinical experience of multiple clinical centers, the Society of Clinical Cancer Research Administration of China Anti-Cancer Association, Breast Cancer Rehabilitation Committee of China Anti-Cancer Association, Chongqing Federation of Clinical Medical Research, and the Society of Onco-endocrinology of Chongqing Anti-Cancer Association thoroughly discussed and formulated the Chinese Expert Consensus on Management of Diabetes and Prediabetes in Female Breast Cancer Patients, in order to further standardize the management of patient’s blood glucose abnormality to improve the patient’s life quality and prognosis. |
Latest registration
